Back to Directory
Alevin Therapeutics
Founded 2022
Small-molecule integrin inhibitors for fibrosis and cancer
Alevin Therapeutics is a biotechnology company developing small-molecule integrin inhibitors for fibrotic diseases and cancer. A University of Nottingham spin-out, it is advancing discovery and preclinical programmes based on a portfolio of RGD-integrin inhibitors. Its research explores selective inhibition of integrin pathways, with potential applications in kidney and liver disease, oncology and targeted drug delivery. The company is headquartered at Mill SciTech Park near Cambridge.